Sickle-Cell Anemia Therapeutics - Global Strategic Business Report

The global market for Sickle-Cell Anemia Therapeutics was estimated at US$2.1 Billion in 2023, and is projected to reach US$4.9 Billion by 2030, growing at a CAGR of 12.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the sickle-cell anemia therapeutics market is driven by several factors. Technological advancements in gene therapy and genome editing are expanding treatment possibilities and improving efficacy. The increasing prevalence of sickle-cell anemia, particularly in regions with high rates of the disease, such as sub-Saharan Africa, India, the Middle East, and certain parts of the United States, is driving demand for effective treatments. Enhanced diagnostic capabilities are facilitating early detection and intervention, which is crucial for managing the disease and improving patient outcomes. Significant investments in research and development by pharmaceutical companies are accelerating the discovery and commercialization of novel therapies. Regulatory support, including orphan drug designations and fast-track approvals, is facilitating quicker access to new treatments. Additionally, the growing adoption of precision medicine is generating demand for personalized therapies tailored to individual genetic profiles. Patient advocacy groups and public health initiatives are also playing a vital role in raising awareness, promoting early diagnosis, and supporting the adoption of innovative treatments, thereby contributing to the overall growth of the sickle-cell anemia therapeutics market.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Hydroxyurea Drug segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 12.0%. The Oxbryta Drug segment is also set to grow at 12.4% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $581.5 Million in 2023, and China, forecasted to grow at an impressive 20.8% CAGR to reach $1.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Sickle-Cell Anemia Therapeutics Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Sickle-Cell Anemia Therapeutics Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Sickle-Cell Anemia Therapeutics Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Agios Pharmaceuticals, Inc., Beam Therapeutics, bluebird bio, Inc., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

Agios Pharmaceuticals, Inc.
Beam Therapeutics
bluebird bio, Inc.
Bristol-Myers Squibb Company
Chiesi Global Rare Disease
CRISPR Therapeutics
CSL Ltd.
Editas Medicine, Inc.
Emmaus Life Sciences, Inc.
GSK Plc
Novartis AG
Novo Nordisk A/S
Pfizer, Inc.
Vertex Pharmaceuticals Inc.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
Global Economic Update
Sickle-Cell Anemia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Prevalence of Sickle-Cell Anemia Spurs Growth in Therapeutics Market
Advances in Gene Therapy Propel Growth
CRISPR Technology Expands Addressable Market Opportunity
Improved Diagnostic Techniques Generate New Opportunities
Here`s How Personalized Medicine is Transforming the Market
Increasing Awareness Throws the Spotlight on Early Diagnosis and Treatment
Expanding Global Healthcare Infrastructure Drives Adoption in Emerging Markets
Biotechnology Innovations Propel Growth in Curative Therapies
Increasing Use of Artificial Intelligence in Drug Discovery Spurs Innovation
Technological Advancements in Blood Transfusion Techniques Generate Demand
Economic Burden of Sickle-Cell Disease Strengthens Business Case for Effective Therapies

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Sickle-Cell Anemia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Hydroxyurea Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Hydroxyurea Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Hydroxyurea Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Oxbryta Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Oxbryta Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Oxbryta Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Adakveo Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Adakveo Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Adakveo Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 17: USA Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 18: USA Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 19: USA 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

CANADA

Table 20: Canada Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 21: Canada Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: Canada 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

JAPAN

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 23: Japan Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 24: Japan Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: Japan 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

CHINA

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 26: China Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 27: China Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: China 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

EUROPE

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 29: Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 30: Europe Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 32: Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: Europe Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

FRANCE

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 35: France Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: France Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: France 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

GERMANY

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 38: Germany Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: Germany Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: Germany 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

ITALY

Table 41: Italy Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: Italy Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: Italy 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

UNITED KINGDOM

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 44: UK Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: UK Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: UK 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

SPAIN

Table 47: Spain Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 48: Spain Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: Spain 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

RUSSIA

Table 50: Russia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Russia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: Russia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 53: Rest of Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 54: Rest of Europe Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 55: Rest of Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 57: Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 58: Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 60: Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 61: Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

AUSTRALIA

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned

Agios Pharmaceuticals, Inc.
Beam Therapeutics
bluebird bio, Inc.
Bristol-Myers Squibb Company
Chiesi Global Rare Disease
CRISPR Therapeutics
CSL Ltd.
Editas Medicine, Inc.
Emmaus Life Sciences, Inc.
GSK Plc
Novartis AG
Novo Nordisk A/S
Pfizer, Inc.
Vertex Pharmaceuticals Inc.

Table Information

Report Attribute	Details
No. of Pages	181
Published	December 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 2.1 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.9 Billion
Compound Annual Growth Rate	12.5%
Regions Covered	Global
No. of Companies Mentioned	14

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5370EUR$5,450USD£4,471GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10202EUR$10,355USD£8,494GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16109EUR$16,350USD£13,412GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 86 Featured):

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Sickle Cell Disease (SCD) - Market Insight, Epidemiology and Market Forecast - 2034

Sickle Cell Disease Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

Sickle Cell Disease Treatment Global Market Report 2024

Hemoglobinopathies - Market Insights, Competitive Landscape, and Market Forecast - 2030

Sickle Cell Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)